



**PRESS RELEASE
FOR IMMEDIATE DISCLOSURE**

**SEMALYTIX AND TURNER HEALTHCARE QUALITY CONSULTING ANNOUNCE
PARTNERSHIP TO HELP PHARMACEUTICAL COMPANIES “HUMANIZE” THE CLINICAL
EXPERIENCE OF PATIENTS**

Philadelphia, PA | April 29, 2021 - Semalytix, a fast-growing German-based start-up company announced that it has entered into a strategic partnership with Turner Healthcare Quality (THCQ) Consulting, Inc. The partnership will help with the adoption of the Semalytix platform, services, and application by pharmaceutical companies in the United States who strive to be at the leading edge of patient-centric drug development and commercialization.

“Current structural challenges with US healthcare access, delivery, and payment can negatively impact the patient experience which, in turn, can result in suboptimal treatment outcomes,” said Norris Turner, President & CEO of THCQ Consulting, Inc. “Understanding the true patient experience is an invaluable perspective when thinking about true value-based, quality healthcare. As we continue to help pharmaceutical companies with clinical development, market access, and market development strategy throughout the development and commercialization stages of new therapies, we are excited to be able to introduce Semalytix as a powerful analytic platform that can help illuminate the patient voice and bring it into strategic engagements and decision making.”

“We are delighted to collaborate with THCQ Consulting on making access to patient-reported insights faster, easier, and more scalable for our partners in the US,” Semalytix CEO Janik Jaskolski commented. “THCQ Consulting combines a wealth of experience with an innovation-first mentality. We are confident that together we can make a meaningful contribution to designing healthcare solutions in a more patient-centric way, ultimately giving more people access to the optimal treatment.”

About Semalytix

Semalytix is committed to helping pharmaceutical companies achieve true patient-centricity in various disease states and languages across the globe. Semalytix’s Pharos is an artificial intelligence-driven research platform that uses authentic and pre-filtered patient data from 25 million online sources (i.e., patient forums) to learn about unknown and unmet patient needs, in addition to disease and treatment experiences. For more information about Semalytix visit www.semalytix.com.

About THCQ Consulting

Turner Healthcare Quality (THCQ) Consulting, Inc. possesses extensive healthcare experience that shapes biopharmaceutical strategy in areas including, but not limited to, clinical development, market access, and market development. THCQ Consulting President & CEO, Norris Turner, PharmD, PhD, possesses a unique professional background, expansive professional network in the U.S. pharmaceutical landscape, and expertise in the pharmaceutical industry. For more information about Turner Healthcare Quality Consulting, Inc., visit www.thcqconsulting.com.

Forward-Looking Statements

Semalytix and THCQ Consulting teams will work jointly to introduce capabilities offered by Semalytix to pharmaceutical companies across the U.S. THCQ Consulting's pharmaceutical industry clients and others with interest will be able to interact with real world data, conduct research, and share insights.

The approach supports discovery of patient-reported unmet needs, treatment gaps as well as satisfaction with the current standard of care for strategic decision making applicable to all stages of the pharmaceutical company product lifecycle. Compared to traditional patient-listening methodologies, it also has the potential to significantly reduce bias and the cost per insight.

More information

Contact person for press inquiries (THCQ Consulting, Inc.):
Norris Turner, PharmD, PhD
nturner@thcqconsulting.com

Contact person for press inquiries (Semalytix):
Yannick Loonus, Chief Sales Officer
yannick.loonus@semalytix.com